Genmab to Outlicense Antibody Following ASH Data Release
BioWorld International Correspondent
LONDON – Genmab A/S is close to outlicensing its second major antibody program – daratumumab – after presenting positive Phase I/II results and said it is determined to avoid the pitfalls that have to date muted the success of its first product, ofatumumab (Arzerra).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST